We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Unlocking Q1 Potential of Haemonetics (HAE): Exploring Wall Street Estimates for Key Metrics
Read MoreHide Full Article
In its upcoming report, Haemonetics (HAE - Free Report) is predicted by Wall Street analysts to post quarterly earnings of $1.01 per share, reflecting a decline of 1% compared to the same period last year. Revenues are forecasted to be $303.28 million, representing a year-over-year decrease of 9.8%.
Over the last 30 days, there has been an upward revision of 0.2% in the consensus EPS estimate for the quarter, leading to its current level. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timeframe.
Ahead of a company's earnings disclosure, it is crucial to give due consideration to changes in earnings estimates. These revisions serve as a noteworthy factor in predicting potential investor reactions to the stock. Numerous empirical studies consistently demonstrate a strong relationship between trends in earnings estimate revision and the short-term price performance of a stock.
While investors typically rely on consensus earnings and revenue estimates to gauge how the business may have fared during the quarter, examining analysts' projections for some of the company's key metrics often helps gain a deeper insight.
With that in mind, let's delve into the average projections of some Haemonetics metrics that are commonly tracked and projected by analysts on Wall Street.
It is projected by analysts that the 'Net revenues- Plasma' will reach $113.65 million. The estimate points to a change of -16.4% from the year-ago quarter.
Analysts expect 'Net revenues- Hospital' to come in at $144.40 million. The estimate indicates a change of +7.8% from the prior-year quarter.
The combined assessment of analysts suggests that 'Net revenues- Blood Center' will likely reach $46.38 million. The estimate indicates a year-over-year change of -30%.
The consensus among analysts is that 'Net revenues- United States' will reach $211.17 million. The estimate suggests a change of -15.2% year over year.
The average prediction of analysts places 'Net revenues- Rest of Asia' at $23.42 million. The estimate points to a change of +18.4% from the year-ago quarter.
Based on the collective assessment of analysts, 'Net revenues- Europe' should arrive at $45.59 million. The estimate indicates a change of -3.5% from the prior-year quarter.
The collective assessment of analysts points to an estimated 'Net revenues- Japan' of $15.99 million. The estimate indicates a change of +16.6% from the prior-year quarter.
Analysts' assessment points toward 'Operating income- Plasma' reaching $59.74 million. Compared to the present estimate, the company reported $65.84 million in the same quarter last year.
The consensus estimate for 'Operating income- Hospital' stands at $27.29 million. The estimate compares to the year-ago value of $53.89 million.
Analysts predict that the 'Operating income- Blood Center' will reach $17.69 million. Compared to the current estimate, the company reported $22.62 million in the same quarter of the previous year.
Over the past month, Haemonetics shares have recorded returns of +0.2% versus the Zacks S&P 500 composite's +0.5% change. Based on its Zacks Rank #3 (Hold), HAE will likely exhibit a performance that aligns with the overall market in the upcoming period. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Unlocking Q1 Potential of Haemonetics (HAE): Exploring Wall Street Estimates for Key Metrics
In its upcoming report, Haemonetics (HAE - Free Report) is predicted by Wall Street analysts to post quarterly earnings of $1.01 per share, reflecting a decline of 1% compared to the same period last year. Revenues are forecasted to be $303.28 million, representing a year-over-year decrease of 9.8%.
Over the last 30 days, there has been an upward revision of 0.2% in the consensus EPS estimate for the quarter, leading to its current level. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timeframe.
Ahead of a company's earnings disclosure, it is crucial to give due consideration to changes in earnings estimates. These revisions serve as a noteworthy factor in predicting potential investor reactions to the stock. Numerous empirical studies consistently demonstrate a strong relationship between trends in earnings estimate revision and the short-term price performance of a stock.
While investors typically rely on consensus earnings and revenue estimates to gauge how the business may have fared during the quarter, examining analysts' projections for some of the company's key metrics often helps gain a deeper insight.
With that in mind, let's delve into the average projections of some Haemonetics metrics that are commonly tracked and projected by analysts on Wall Street.
It is projected by analysts that the 'Net revenues- Plasma' will reach $113.65 million. The estimate points to a change of -16.4% from the year-ago quarter.
Analysts expect 'Net revenues- Hospital' to come in at $144.40 million. The estimate indicates a change of +7.8% from the prior-year quarter.
The combined assessment of analysts suggests that 'Net revenues- Blood Center' will likely reach $46.38 million. The estimate indicates a year-over-year change of -30%.
The consensus among analysts is that 'Net revenues- United States' will reach $211.17 million. The estimate suggests a change of -15.2% year over year.
The average prediction of analysts places 'Net revenues- Rest of Asia' at $23.42 million. The estimate points to a change of +18.4% from the year-ago quarter.
Based on the collective assessment of analysts, 'Net revenues- Europe' should arrive at $45.59 million. The estimate indicates a change of -3.5% from the prior-year quarter.
The collective assessment of analysts points to an estimated 'Net revenues- Japan' of $15.99 million. The estimate indicates a change of +16.6% from the prior-year quarter.
Analysts' assessment points toward 'Operating income- Plasma' reaching $59.74 million. Compared to the present estimate, the company reported $65.84 million in the same quarter last year.
The consensus estimate for 'Operating income- Hospital' stands at $27.29 million. The estimate compares to the year-ago value of $53.89 million.
Analysts predict that the 'Operating income- Blood Center' will reach $17.69 million. Compared to the current estimate, the company reported $22.62 million in the same quarter of the previous year.
View all Key Company Metrics for Haemonetics here>>>Over the past month, Haemonetics shares have recorded returns of +0.2% versus the Zacks S&P 500 composite's +0.5% change. Based on its Zacks Rank #3 (Hold), HAE will likely exhibit a performance that aligns with the overall market in the upcoming period. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .